BioRestorative Therapies Inc (BRTX)

[stervc]

BRTXQ vs MESO:NASDAQ**Compare & Contrast...

I recommend all to read Slide #16 below within the BRTXQ presentation to "Compare and Contrast" key thoughts regarding BRTXQ and MESO:NASDAQ to see why BRTXQ is bringing to the table something better than what MESO:NASDAQ is trying to bring into the market. Read below to understand why I believe BRTXQ is significantly undervalued...

BRTXQ = Trades on OTC Markets
MESO = Trades on the NASDAQ

BRTXQ = Closed at .0039 per share
MESO = Closed at $11.81 per share

BRTXQ Market Cap = $6,392,893 https://www.otcmarkets.com/stock/BRTXQ/profile
MESO Market Cap = $235,551,022 https://www.otcmarkets.com/stock/MESO/profile

BRTXQ Website: http://www.biorestorative.com/
MESO Website: http://www.mesoblast.com/

BRTXQ Stem Cell Product/Treatment = BRTX-100
MESO Stem Cell Product/Treatment = MPC-06-ID

BRTXQ Stem Cell Product Status = FDA Approved Phase II (under active IND 17275)
MESO Stem Cell Product Status = FDA Approved Phase III

BRTXQ Stem Cell Product Results/Findings = Good
MESO Stem Cell Product Results/Findings = Not so Good

Before reviewing the slide, read the reasons why BRTX-100 is a more superior product because of what it has versus what the other doesn't below:

• Autologous cells means low to no risk of rejection, greater safety profile (introduction of viral/genetic), potentially streamlined regulatory path.
• Hypoxic culturing creates increased cell proliferation, greater plasticity, increased paracrine effect and increased cell survival after application.
• Autologous platelet lysate provides growth factors that interact with the cells, allowing for better cell survival.
• Low to no risk of safety concerns related to immunological and zoonotic (animal to people) transmission.
• Strong runway for value creation with successful clinical results.

http://www.biorestorative.com/wp-content/uploads/2019/09/BRTX-Presentation-Fall-2019.pdf?fbclid=IwAR3TXVlEi61W8X8ourYrWcHV4_ekOiZxIhDYzF8Ny-VD2UlaPODmYGYzWJI

v/r
Sterling